58 jili casino
The latest developments in the Taiwan Strait highlight the complex and sensitive nature of cross-strait relations. The Chinese government remains committed to upholding the One China principle and seeking peaceful reunification with Taiwan, but will not hesitate to defend its territorial integrity and national interests.One of the key factors driving this bullish sentiment is the improving macroeconomic environment in China. The country's economy has shown resilience in the face of various challenges, with GDP growth remaining strong and inflation concerns being managed effectively. Additionally, the government's commitment to supporting economic growth through targeted policies and reforms has boosted investor confidence in the market's long-term prospects.
LAS VEGAS , Dec. 16, 2024 /PRNewswire/ -- CTLA-4 inhibitors are a well-established market in cancer care, and they are expected to grow significantly in the coming years. This is due to the expected label expansion and usage of the blockbuster YERVOY and an increasing number of new clinical studies evaluating better-acting versions of CTLA-4 inhibitors in various types of cancers. Other market drivers include increased usage of CTLA-4 inhibitors in combination with other immune checkpoint inhibitors and the increasing prevalence of cancer cases. DelveInsight's CTLA-4 Inhibitors Market Insights report includes a comprehensive understanding of current treatment practices, emerging CTLA-4 inhibitors, market share of individual therapies, and current and forecasted CTLA-4 inhibitors market size from 2020 to 2034, segmented into 7MM [ the United States , the EU4 ( Germany , France , Italy , and Spain ), the United Kingdom , and Japan ]. Key Takeaways from the CTLA-4 Inhibitors Market Report As per DelveInsight's analysis, the total market size of CTLA-4 inhibitors in the 7MM is expected to surge significantly by 2034. In 2023, YERVOY registered global sales of more than USD 2 billion , followed by IMJUDO which closed 2023 with more than USD 200 million in global sales. YERVOY in combination with OPDIVO is approved for multiple indications in first-line settings including metastatic Melanoma, mesothelioma, Renal Cell Carcinoma, NSCLC, Esophageal cancer, Gastric Cancer, and other second-line indications. There are other newer indications where the combo is being evaluated. Established CTLA-4 inhibitor companies include Bristol Myers Squibb (BMS) and AstraZeneca, Leading emerging CTLA-4 inhibitor companies such as Merck , Xilio therapeutics, BioNTech, Agenus, Bioatla OncoC4, and others are developing novel CTLA-4 inhibitors that can be available in the CTLA-4 inhibitors market in the coming years. Some of the key CTLA-4 inhibitors in the pipeline include Quavonlimab (MK-1308), gotistobart ( ONC-392/BN316 ), BA3071 , and others. Discover which therapies are expected to grab the CTLA-4 inhibitors market share @ CTLA-4 Inhibitors Market Report CTLA-4 Inhibitors Market Dynamics In recent years, the CTLA-4 inhibitors market has been shaped by significant advances in cancer immunotherapy. The growing use of combination therapies , particularly the pairing of CTLA-4 inhibitors with PD-1/PD-L1 inhibitors (like nivolumab or pembrolizumab), has transformed the treatment landscape for several cancers, including melanoma, renal cell carcinoma, and non-small cell lung cancer (NSCLC). This combination approach has demonstrated improved survival benefits , broadening the market for CTLA-4 inhibitors beyond their original monotherapy applications. Additionally, research is ongoing to explore the use of these drugs in other cancers such as colorectal and pancreatic cancer, further fueling market growth. However, market dynamics are influenced by several factors, including the high cost of immunotherapy treatments and the side effects associated with CTLA-4 inhibitors . Immune-related adverse events (irAEs) like colitis, hepatitis, and dermatitis are common due to the drug's effect of ramping up immune activity. As a result, healthcare providers are cautious in prescribing these treatments , and pharmaceutical companies are working on optimizing dosing regimens and exploring biomarkers that could predict which patients will respond best to CTLA-4 inhibition. These considerations impact pricing, regulatory approval, and overall market uptake. The competitive landscape is also heating up as more pharmaceutical companies enter the immunotherapy space. While Bristol- Myers Squibb's ipilimumab has dominated the market, new players and biosimilars are emerging. Additionally, research into next-generation CTLA-4 inhibitors and alternative immune checkpoint targets (like LAG-3 and TIGIT) could change the market dynamics further. The evolution and improvisation of this class can be seen through the development of Fc-enhanced tumor-activated anti-CTLA-4 inhibitors (Xilio's Therapeutics' Vilastobart) which also deplete regulatory T cells when activated (unmasked) in the tumor microenvironment (TME). The innovations in drug delivery and therapeutic combinations , is likely to drive new developments in this area, attracting substantial investment and strategic partnerships. Overall, the CTLA-4 inhibitors market remains highly promising, buoyed by the increasing global burden of cancer , the expanding role of immunotherapy in oncology, and the significant unmet need in the treatment of several aggressive cancers. Advances in research and clinical trials , along with ongoing regulatory approvals, are expected to keep this market growing in the foreseeable future. However, balancing efficacy, safety, and cost will be critical for both pharmaceutical companies and healthcare providers to ensure the sustained success of CTLA-4 inhibitors. CTLA-4 Inhibitors Treatment Market Approved CTLA-4 inhibitors at present are YERVOY (ipilimumab) and IMJUDO (tremelimumab-actl). In March 2011 , YERVOY was the first cancer immunotherapy approved for melanoma, specifically targeting CTLA-4. At that time, it was the only approved treatment for unresectable or metastatic melanoma that showed a significant enhancement in overall survival. The FDA's approval of YERVOY represents the result of over 14 years of research and development by BMS teams, as well as clinical trials involving 676 patients with unresectable or metastatic melanoma who had previously received one or more treatments, including aldesleukin, dacarbazine, temozolomide, fotemustine, or carboplatin, in a randomized Phase III clinical trial. IMJUDO is a human monoclonal antibody designed to inhibit the activity of CTLA-4. By blocking CTLA-4, it promotes T-cell activation, which enhances the immune response against cancer and encourages the destruction of cancer cells. With its initial regulatory approval, patients in the US suffering from unresectable liver cancer now have access to an approved dual immunotherapy treatment regimen that uniquely combines CTLA-4 inhibition with a PD-L1 inhibitor, thereby amplifying the immune response to their cancer. YERVOY currently leads the CTLA-4 inhibitor market, generating over USD 2 billion in sales in 2023, while IMJUDO ended the year with sales exceeding USD 200 million . However, numerous CTLA-4 inhibitors are in clinical trials, with some utilizing innovative proprietary technologies in their development, which could pose a significant challenge to YERVOY's market dominance in the future. Learn more about the FDA-approved CTLA-4 inhibitors @ CTLA-4 Inhibitors Drugs Key Emerging CTLA-4 Inhibitors and Companies Several key emerging players, including Merck, BioNTech, Agenus, BioAtla , and others, are involved in developing drugs for CTLA-4 inhibitors for various indications such as metastatic castration-resistant prostate cancer, breast cancer, cervical cancer, non-squamous cell lung cancer, and others. OncoC4/BioNTech's BNT316/ONC-392 (gotistobart) is a next-generation anti-CTLA-4 antibody being co-developed by BioNTech and OncoC4. It is in late-stage clinical trials, either as a monotherapy or in combination with other treatments, targeting various cancers including non-small cell lung cancer, ovarian cancer, high-grade serous adenocarcinoma of the ovary, primary peritoneal carcinoma, and fallopian tube cancer. CTLA-4 is an immune checkpoint receptor that suppresses T cell responses, limiting their ability to identify and destroy cancer cells. Gotistobart is designed to counteract this suppression while maintaining CTLA-4 recycling, which helps preserve T cell immunosuppressive function in peripheral tissues. This approach, now under clinical evaluation, aims to reduce immune-related side effects. BioAtla's BA3071 is a conditionally active biologic (CAB) anti-CTLA-4 antibody being developed as an immuno-oncology agent. It aims to provide efficacy comparable to existing anti-CTLA-4 antibodies, but with reduced toxicity due to its selective activity in the tumor microenvironment. While blocking CTLA-4 has been shown to enhance antitumor responses, it can also cause immune-related damage to healthy cells. To reduce this risk of on-target, off-tumor effects, BioAtla has used its proprietary CAB technology to ensure that BA3071 binds to the CTLA-4 receptor only on T cells within the tumor microenvironment. This design is intended to enhance both the efficacy and safety of anti-CTLA-4 therapy, whether used alone or in combination with other treatments, by activating T cells specifically in the tumor site. BA3071 is currently in Phase II trials for treating various solid tumors that respond to CTLA-4 inhibition in combination with a PD-1 blocking agent. The anticipated launch of these emerging therapies are poised to transform the CTLA-4 inhibitors market landscape in the coming years. As these cutting-edge therapies continue to mature and gain regulatory approval, they are expected to reshape the CTLA-4 inhibitors market landscape, offering new standards of care and unlocking opportunities for medical innovation and economic growth. To know more about CTLA-4 inhibitors clinical trials, visit @ CTLA-4 Inhibitors Treatment Drugs CTLA-4 Inhibitors Overview CTLA-4 inhibitors are a class of immune checkpoint inhibitors that target cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), a protein expressed in T cells. CTLA-4 plays a crucial role in downregulating immune responses by binding to B7 molecules on antigen-presenting cells (APCs), which suppresses T-cell activation. By inhibiting CTLA-4, these drugs block the suppression of T cells, thereby enhancing the immune system's ability to recognize and destroy cancer cells. This mechanism has made CTLA-4 inhibitors an essential part of cancer immunotherapy, particularly in treating advanced-stage malignancies like melanoma. Ipilimumab, the first approved CTLA-4 inhibitor, has shown significant survival benefits in clinical trials, leading to its use in combination with other immune checkpoint inhibitors, such as PD-1 inhibitors, to further improve patient outcomes. While CTLA-4 inhibitors have shown promise in cancer therapy, their use comes with challenges, particularly immune-related adverse events (irAEs). These adverse effects occur because the inhibition of CTLA-4 can lead to excessive immune activation, which may result in the immune system attacking normal tissues and organs. Common irAEs include colitis, dermatitis, and hepatitis. Managing these side effects requires a delicate balance between maintaining the anti-cancer immune response and mitigating harmful autoimmune reactions. Despite these challenges, the clinical benefits of CTLA-4 inhibitors have made them a vital component in the fight against cancer, driving ongoing research into their optimization and use in combination therapies. Scope of the CTLA-4 Inhibitors Market Report CTLA-4 Inhibitors Therapeutic Assessment: CTLA-4 Inhibitors current marketed and emerging therapies CTLA-4 Inhibitors Market Dynamics: Conjoint Analysis of Emerging CTLA-4 Inhibitors Drugs Competitive Intelligence Analysis: SWOT analysis and Market entry strategies Unmet Needs, KOL's views, Analyst's views, CTLA-4 Inhibitors Market Access and Reimbursement Discover more about CTLA-4 inhibitors in development @ CTLA-4 Inhibitors Clinical Trials Table of Contents Related Reports Non-small Cell Lung Cancer Market Non-small Cell Lung Cancer Market Insight, Epidemiology and Market Forecast – 2032 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key NSCLC companies, including EMD Serono, Merck, Cellular Biomedicine Group, Inc., Celgene, CellSight Technologies, Inc., BeyondSpring Pharmaceuticals Inc., J Ints Bio, Forward Pharmaceuticals Co., Ltd., AstraZeneca, Bristol-Myers Squibb, Teligene US, Rain Oncology Inc, ReHeva Biosciences, Inc., Amgen, Novartis, RedCloud Bio, Parexel, Vitrac Therapeutics, LLC, Mythic Therapeutics, Instil Bio, Mirati Therapeutics Inc., Daiichi Sankyo, Inc., AstraZeneca, Precision Biologics, Inc, Promontory Therapeutics Inc., Palobiofarma SL, Regeneron Pharmaceuticals, Revolution Medicines, Inc., Cullinan Oncology, LLC, Iovance Biotherapeutics, Inc., Innate Pharma , among others. Non-small Cell Lung Cancer Pipeline Non-small Cell Lung Cancer Pipeline Insight – 2024 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key non-small cell lung cancer companies, including BridgeBio Pharma, Daiichi Sankyo, EMD Serono, Merck, BridgeBio Pharma, Abbvie, Pfizer, Eli Lilly and Company BioNTech SE, Shenzhen TargetRx, Taiho Pharmaceutical, Chong Kun Dang , Bristol Myers Squibb, Innovent Biologics, Xuanzhu Biopharmaceutical, Bayer, GeneScience Pharmaceuticals, InventisBio, Apollomics, Imugene, Ono Pharmaceutical, Pierre Fabre , Jiangsu Hengrui Medicine Co., Bristol-Myers Squibb, Surface Oncology, Inhibrx, Sinocelltech, Mirati Therapeutics, REVOLUTION Medicines, Yong Shun Technology Development, Iovance Biotherapeutics, Galecto Biotech, among others. Ovarian Cancer Market Ovarian Cancer Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, market share of the individual therapies, and key ovarian cancer companies including Allarity Therapeutics, OSE Immunotherapeutic, Cristal Therapeutics, Bristol-Myers Squibb, Ono Pharmaceuticals, Merck & Co, Aravive Biologics, Mersana Therapeutics, Clovis Oncology, Verastem Oncology, Gradalis, VBL Therapeutics, AbbVie, Elevation oncology, OncoQuest Pharmaceuticals (CanariaBio), Alkermes, Hoffman-la Roche, AstraZeneca, MSD, GlaxoSmithKline, IMV, Corcept Therapeutics , among others. Ovarian Cancer Pipeline Ovarian Cancer Pipeline Insight – 2024 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key ovarian cancer companies, including Gradalis, VBL Therapeutics, AbbVie, Elevation oncology, OncoQuest Pharmaceuticals (CanariaBio), Alkermes, Hoffman-la Roche, among others. About DelveInsight DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve . Contact Us Shruti Thakur [email protected] +14699457679 Logo: https://mma.prnewswire.com/media/1082265/3528414/DelveInsight_Logo.jpg SOURCE DelveInsight Business Research, LLP
In conclusion, the tale of the former Barcelona star's precipitous fall from grace and subsequent resurgence at Liverpool is a testament to the unpredictable nature of football. In a sport where fortunes can change in an instant, the Reds' bold move to invest heavily in a player on the decline could prove to be a masterstroke. Only time will tell if this gamble pays off, but one thing is certain – the footballing world will be watching with bated breath as this fascinating story unfolds.
The Prime Minister is set to visit British troops serving on Russia’s border as he says Ukraine will require more funding and capability. Sir Keir Starmer was speaking at the Joint Expeditionary Force (JEF) conference in Estonia where he met leaders of other Baltic states. After signing an energy partnership with Norwegian Prime Minister Jonas Gahr Store in Bergen, Sir Keir flew to Estonia where he spoke alongside Mr Store and their Estonian counterpart Kristen Michal. He added: “A lot of money has been raised, funding has been raised, but more is going to be needed.” The Prime Minister’s also discussed making the economic case at home for continued support for Ukraine. “Now, this is a different world to the world of 10, 20 years ago, to recognise the world that we are living in, there’s a positive case as well to be made. “Defence spending doesn’t sort of sit in a silo over here with no effect on the rest of the economy, no effect on technology. “It has a huge effect on technologies, the cutting edge of technology and change which can then be used in other areas. “It binds countries together. I think all of us have got joint projects on in terms of defence capabilities that bind us together. There’s a huge number of well-paid jobs that are very important to our economy in defence spending as well. “But we have to make that positive case. I don’t personally feel that we can sort of sit back and assume that all of those in our respective countries necessarily accept all of our arguments unless we make them in that positive way, which I do think the argument can and should and must be made. “But the challenge that you put to us is the right challenge, which is it’s very difficult when finances are tight, as they are in all of our countries.” Specialising in the manufacture of the missiles, the rapidly growing company already collaborates closely with the UK defence industry, sourcing a significant portion of its subsystems locally, including from propulsion specialists Roxel in Worcestershire. The Prime Minister will again attend the JEF summit, joining leaders from the Nordics and Baltics to discuss support for Ukraine, the sustained threat posed by Russia and wider European security. He will then visit British forces serving in the region to deter malign Russian threats.As the investigation into the cause of the fire continues, questions arise about the vulnerabilities and risks associated with storing and processing vast amounts of sensitive data in high-tech facilities. The incident serves as a stark reminder of the importance of implementing robust safety protocols and contingency measures to prevent and mitigate the impact of such emergencies in the future. Organizations must be vigilant and proactive in safeguarding their data centers and infrastructure against potential threats, both external and internal, to ensure the security and reliability of their services.
ollo This monthly article series reports fundamental and momentum metrics in the industrial sector. It is also a top-down analysis of sector ETFs like The Industrial Select Sector SPDR® Fund ETF ( XLI ), Fidelity MSCI Industrials Index ETF ( Quantitative Risk & Value (QRV) provides you with risk indicators and data-driven, time-tested strategies. Get started with a two-week free trial now. Fred Piard, PhD. is a quantitative analyst and IT professional with over 30 years of experience working in technology. He is the author of three books and has been investing in data-driven systematic strategies since 2010. Quantitative Risk & Value Learn more Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article. Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.Representative image NEW DELHI: After months of sluggish sales, strong demand for derma and cardiac drugs drove the organised pharma retail market to double-digit growth in Nov, with heavy pollution in several parts of the country boosting Foracort sales. The medication, used for asthma and respiratory issues, topped the market in Nov with sales of Rs 82 crore, according to the latest data culled by TOI from IQVIA. Foracort assumed the top slot in Nov with a growth of 2%, while antibiotic Augmentin ranked second with a growth of 9% registering Rs 76 crore sales, and antidiabetic therapy Glycomet GP, ranked third, was almost flat at Rs 69 crore. In terms of therapies, urology led the growth with 18% rise, while the derma, cardiac, and pain-relief segments followed with growth rates of 16%, 13%, and 13%, respectively. Further, pain-relief medication Zerodol SP posted a growth of 22%, while others which grew over 20% month-on-month include Ryzodeg, Rosuvas, Cilacar, Rybelsus and Duphalac. Sun Pharma continued to lead the pack with a share of 8% in the overall pharma retail market valued at Rs 2,28,059 crore. Cipla and Dr Reddy's also increased their share month on month. During the month, both acute - mainly painkillers and anti-infectives - and chronic medication, those prescribed for long-term ailments, posted a double-digit growth of 11% each. "After a lull for the last three months, industry volumes reported positive growth of 3.5%. Rebound in growth for anti-infectives was led by key molecules like amoxicillin+clavulanic acid and ceftriaxone, pantoprazole+domperidone combination was main growth driver for gastro-intestinal therapy, cough syrups, formoteral+budesonide and levocetirizine+montelukast drove growth in respiratory therapies,'' an analyst from ICICI said. Domestic companies registered growth of nearly 11%, whereas MNCs grew just over 10%. In 2025, the market will continue to grow by high-single digits, led by price increase and new launches, while volume growth remains muted, an analyst from HSBC told TOI. "In 2025, we assume Indian companies will start their journey in GLP-1 (Glucagon-like peptide-1) drugs with the launch of generic liraglutide," he added. GLP-1 is a hormone that helps control blood sugar levels and plays a role in weight management. Globally, MNCs including Novo Nordisk and Eli Lilly have launched blockbuster drugs for obesity and diabetes, which are expected to be launched in India over the next few years. Ready to Master Stock Valuation? ET’s Workshop is just around the corner!
John Stamos rips backlash over bald cap tribute to Dave CoulierPlayers who were found to be cheating have been blocked from accessing the game and all progress on their accounts has been reset. The developers have also issued a warning to other players that cheating will result in similar consequences, urging them to play the game fairly and respect the rules set forth by the game.
Go Woke, Go BROKE: Jaguar Stock Prices Tumble After Backlash to Cringe Rebranding AdOde To Our Land To Screen At Msheireb Downtown DohaTitle: Unconventional Countercyclical Adjustment, Stabilizing Real Estate and Stock Markets through Moderate EasingWhat sets this new technology apart from previous advancements is its comprehensive approach to speed enhancement. While previous innovations may have focused on improving speed in specific areas or applications, the Swift-X algorithm is able to deliver unparalleled performance improvements across the board. This means that users can expect to see a dramatic increase in speed and efficiency no matter what task they are performing, whether it's running complex simulations, analyzing large datasets, or streaming high-definition video.
In conclusion, the internet celebrity who has shed the long robe of conformity is not just a trendsetter or a provocateur - they are a trailblazer, forging a new path in the digital landscape. By constructing a vast "edgy" universe that pushes the boundaries of acceptability and challenges the norms of society, they are demanding attention, sparking conversation, and redefining what it means to be a public figure in the age of social media. Love them or hate them, one thing is clear - they are here to stay, and their influence on the digital world is only just beginning.A compromise version of Mayor Eric Adams’ zoning overhaul aimed at easing the city’s dire housing crisis squeaked through the City Council on Thursday, clearing its final hurdle to become law. The mayor’s “City of Yes for Housing Opportunity” plan, a suite of proposals that promises to allow for “a little more housing in every neighborhood,” passed the 51-member chamber by a slim 31-20 votes on Dec. 5. The city estimates the plan will spur the construction of 82,000 new housing units over the next 15 years, down from the 109,000 homes it was projected to produce before the council’s modifications were made. All that remains is for Adams to sign what will likely be his greatest signature accomplishment as mayor thus far into law. Adams, during a City Hall rally on the heels of the vote, compared his administration to the 1986 Mets team that won the World Series. “We’re gonna argue in the locker room, we’re gonna get in debates, we’re going to do all sorts of things, but you know what? We’re gonna bring home the championship ring,” Adams said. “That’s what we did...You’re seeing the most comprehensive housing reform in the history of the city.” City Council Speaker Adrienne Adams, following several council members’ impassioned speeches for and against the plan, said the body “cannot do nothing” about the city’s dire housing crisis. She also emphasized that the modified version of the zoning text amendment hashed out by the council is far better than what the mayor initially proposed. “This council cannot be the body that says ‘no’ to people that need a place to live,” Speaker Adams said in an emotional speech. “This cannot be the council that turns their back on homeless; this cannot be the council that continues to say ‘scrap it, let’s move ahead and do something else,’ because I tell you that will never happen.” The plan consists of a series of updates to city zoning rules that have not been changed in over half a century. It’s designed to expand the amount of housing that can be built in parts of the Big Apple that typically do not see much development. The zoning changes only narrowly passed the city legislature even after they were altered last month to assuage many council members’ concerns about them potentially altering the character of the neighborhoods they represent. The final deal between City Hall and the council also includes a $5 billion commitment from Adams’ office and Gov. Kathy Hochul to fund affordable housing construction, housing affordability programs, infrastructure improvements, and more staff for city housing agencies. Several council members acknowledged that the modifications addressed their concerns and got them to a “yes.” Why they voted ‘no’ The lawmakers who voted against the City of Yes included every member of the chamber’s conservative Common Sense Caucus, some Democratic members representing low-rise outer-borough neighborhoods, and one progressive who saw the plan as a giveaway to developers. City Council Member Joann Ariola (R-Queens) said her “no” vote was driven by her constituents’ concerns that City of Yes would change the character of their neighborhoods. She also expressed concerns that the infrastructure in her district, which covers coastal areas in the Rockaways, will not be able to support the added housing that would come with the plan. “The city of yes will only add to the heavy burden that residents face every day,” Ariola said. “We don’t have the infrastructure and I know the mayor has promised money for infrastructure. But why are we putting the cart before the horse? Why are we putting the housing up and then worrying about the infrastructure?” David Carr, a Republican council member representing Staten Island, who also voted “no,” said he believes the plan is “incredibly vulnerable to legal action” and “will not survive” such action, which could be forthcoming. Progressive Council Member Christopher Marte (D-Manhattan) said he voted against the plan because it is a “yes to only the real estate developers.” ‘The real controversy’ On the other hand, Council Member Crystal Hudson (D-Brooklyn) said the proposal rightfully forces areas that have never built much housing to begin doing their part. She pointed out that areas like the South Bronx have borne the brunt of new development for far too many years. “The reality is that some communities are doing their part to address the housing crisis and others are not, and that’s the real controversy,” Hudson said. “This first-of-its-kind citywide text amendment does the bare minimum to create opportunities to build housing.” The original plan included proposals such as eliminating a mandate that new projects include a certain number of off-street parking spots, allowing new units to be built next to or within existing homes—known as accessory dwelling units (ADUs)—and clearing the way for 3-to-5-story construction near train stations and on top of storefronts. Other provisions in the scheme would permit developers to build at least 20% more housing in their projects as long as it is affordable and allow construction on large open areas owned by organizations like houses of worship. However, several of those measures were altered in response to council members’ concerns. Therefore, the amended version of the plan will not completely eliminate parking mandates. Instead, it will split the city into three zones where the requirement will be lifted, reduced, or kept in place. Furthermore, ADUs on ground floors and in basements will not be permitted in flood zones, and those in backyards will be barred from some areas, including historic districts. The provisions allowing for three-to-five-story construction near train stations and above storefronts—known as transit-oriented development and town-center zoning, respectively—were also modified. One of the changes will require developers who build 50 units or more in either type of project to make at least 20% of the units affordable at 80% of the area median income. The $5 billion secured by the council includes $2 billion specifically for affordable housing construction and renovation. Another $2 billion will go toward improving the infrastructure of the areas that could see more housing production under the plan, including sewer upgrades, stormwater drainage improvements, and flood mitigation. Other funding in the deal goes toward homeownership programs, tenant protections, city-funded housing vouchers, and increased housing agency staffing levels.Marta's magic helped get the Pride to Saturday's NWSL title game against the Washington Spirit
Georgetown is set to play its first road game of the season while West Virginia attempts to build off its successful 2-1 trip to the Bahamas when the former conference rivals meet on Friday in Morgantown, W. Va., as part of the Big 12-Big East Battle. Picked 13th out of 16 in the Big 12 preseason coaches' poll, West Virginia (5-2) has been riding the hot shooting of Javon Small and Tucker DeVries. Small averages a team-high 19 points and shoots 41.3 percent on 3-pointers while DeVries adds 14.9 points per game and hits on 46.9 percent of his threes. Every basket was needed last week as the Mountaineers upset then-No. 3 Gonzaga and then-No. 24 Arizona with a loss to Louisville sandwiched in between. All three contests went into overtime, believed to be a first in program history. First-year coach Darian DeVries, who led Drake to three NCAA Tournaments in the last four seasons, had never seen anything like it. "I've never been a part of three games like that, especially with the quality of opponents that we went up these last three days," he said after the Arizona win. "Just incredible resolve and grit and toughness from our group all three nights." Georgetown has started 7-1 for the first time since the 2018-19 season and has done so with a completely revamped roster that includes 14 freshmen or sophomores. As a result of an inexperienced squad, coach Ed Cooley specifically delayed the Hoyas' first trip out of the nation's capital. "Obviously, the competition is going to change," Cooley said after the Hoyas defeated UMBC 86-62 on Monday. "We systematically scheduled this way to build confidence, continuity and chemistry and let our players feel what it is to win, and that's something hopefully that will have some carryover as we now get ready to head out on the road for the first time." Since losing to Notre Dame on Nov. 16, Georgetown has won five straight games by an average of 25.2 points. Thomas Sorber leads the Hoyas in scoring at 15.8 points per game and leads the conference in rebounding at 8.9 per game. Sorber was named as the Big East Freshman of the Week for the third time in four weeks. Georgetown holds the narrowest of leads in the all-time series at 27-26. The two schools met 27 times between 1995 and 2012 as league foes. The Mountaineers captured their lone Big East Championship in 2010 by defeating the Hoyas 60-58 at Madison Square Garden. --Field Level Media
As he basks in the glory of his latest triumph, Shi Yuqi understands the importance of staying motivated and focused on his goals. He recognizes that the path to success is not always smooth, but he remains determined to face any challenges head-on with courage and determination. Shi Yuqi's positive attitude and strong work ethic serve as an inspiration to aspiring athletes around the world, encouraging them to pursue their dreams with passion and determination.Georgetown is set to play its first road game of the season while West Virginia attempts to build off its successful 2-1 trip to the Bahamas when the former conference rivals meet on Friday in Morgantown, W. Va., as part of the Big 12-Big East Battle. Picked 13th out of 16 in the Big 12 preseason coaches' poll, West Virginia (5-2) has been riding the hot shooting of Javon Small and Tucker DeVries. Small averages a team-high 19 points and shoots 41.3 percent on 3-pointers while DeVries adds 14.9 points per game and hits on 46.9 percent of his threes. Every basket was needed last week as the Mountaineers upset then-No. 3 Gonzaga and then-No. 24 Arizona with a loss to Louisville sandwiched in between. All three contests went into overtime, believed to be a first in program history. First-year coach Darian DeVries, who led Drake to three NCAA Tournaments in the last four seasons, had never seen anything like it. "I've never been a part of three games like that, especially with the quality of opponents that we went up these last three days," he said after the Arizona win. "Just incredible resolve and grit and toughness from our group all three nights." Georgetown has started 7-1 for the first time since the 2018-19 season and has done so with a completely revamped roster that includes 14 freshmen or sophomores. As a result of an inexperienced squad, coach Ed Cooley specifically delayed the Hoyas' first trip out of the nation's capital. "Obviously, the competition is going to change," Cooley said after the Hoyas defeated UMBC 86-62 on Monday. "We systematically scheduled this way to build confidence, continuity and chemistry and let our players feel what it is to win, and that's something hopefully that will have some carryover as we now get ready to head out on the road for the first time." Since losing to Notre Dame on Nov. 16, Georgetown has won five straight games by an average of 25.2 points. Thomas Sorber leads the Hoyas in scoring at 15.8 points per game and leads the conference in rebounding at 8.9 per game. Sorber was named as the Big East Freshman of the Week for the third time in four weeks. Georgetown holds the narrowest of leads in the all-time series at 27-26. The two schools met 27 times between 1995 and 2012 as league foes. The Mountaineers captured their lone Big East Championship in 2010 by defeating the Hoyas 60-58 at Madison Square Garden. --Field Level Media
In response to the incident, local authorities have launched an investigation to determine the source of the carbon monoxide leak and to hold responsible parties accountable for the safety lapse. The bathhouse has been temporarily closed for further inspection and remediation measures to eliminate any potential risks of carbon monoxide exposure.The benefits of implementing a 5-hour workday extend beyond improved productivity and customer service. By offering employees more flexibility in their work schedules, Pangtong Corporation demonstrates its commitment to fostering a positive work environment and supporting the well-being of its workforce. This employee-centric approach is expected to result in higher employee retention rates, increased job satisfaction, and enhanced overall workplace morale.